Physicians Side with Big Pharma in Biosimilar Name Debate
The ongoing debate over whether biosimilars should be given the same INN as brand-name biologics has divided the healthcare industry.
Supply Chain Security Breaches Increase Regulatory Scrutiny, Says Dow Corning
OEMs must comply with additional regulatory requirements
All-Star Innovators 2014
Pharma’s tech bench gets deeper with an All-Star lineup ready for the big leagues
How and why Baxter International implemented an automated continued process verification program